Previous 10 | Next 10 |
- Newly granted U.S. patent further strengthens the Company’s leadership position in the deuterated tryptamine space - - With the recently announced definitive agreement to acquire Small Pharma Inc. The granted patent will add to the most impressive intellectual property portfolio ...
2023-08-31 12:35:49 ET More on psychedelic drugmakers Compass Pathways: Debt Deal Secured, Cash Runway Extended COMPASS Pathways plc ( CMPS ) Q2 2023 Earnings Call Transcript Mind Medicine Inc. ( MNMD ) Q2 2023 Earnings Call Transcript Psychedelic Sto...
2023-08-28 11:18:10 ET More on Cybin, Small Pharma Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. Psychedelic Stocks: Don't Bet On Just 1 Company Cybin renews $35M ATM equity offering Cybin stock falls on pricing discounted stock and ...
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy - - Combined portfolio creates the indust...
Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, announced that it has renewed its previously established at-the-market equity program. The ...
2023-08-24 06:18:26 ET More on Cybin Cybin stock falls on pricing discounted stock and warrants offering Cybin stock slumps 25% on equity offering Watch these psychedelic stocks as sector faces year of 'collapse and consolidation' Seeking Alpha’s Quant...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today that it ha...
2023-08-22 12:50:11 ET More on psychedelic drug companies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down Psychedelic Stocks: Don't Bet On Just 1 Company Seelos:...
Cybin (NYSE American: CYBN) (NEO: CYBN) was featured in a recent interview with Proactive Investors that covers protection of the company’s IP with the granting of a second U.S. patent for its its deuterated analog programs. Cybin CEO Doug Drysdale joined Steve Darling from Proactive to...
--News Direct-- Cybin Inc CEO Doug Drysdale joined Steve Darling from Proactive to share news the US Patent and Trademark Office has granted another patent to a deuterated psilocybin analog within the company's CYB003 investigational drug program. This patent is expected to provide ex...
News, Short Squeeze, Breakout and More Instantly...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases followi...
Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser , Cybin highlighted k...